Literature DB >> 11257027

Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis.

S Buates1, G Matlashewski.   

Abstract

S-28463 and imiquimod are imidazoquinoline compounds which stimulate microbicidal activity by inducing a local immune response at the site of application. Imiquimod-containing cream is an effective clinical treatment against cervical warts caused by human papillomavirus infection. Imiquimod also induces leishmanicidal activity both in vitro in macrophages and in vivo in a mouse model for cutaneous leishmaniasis. The major target cells of S-28463 and imiquimod are macrophages. To explore the molecular basis in which imidazoquinolines generate macrophage microbicidal activity, a cDNA gene array analysis was undertaken to identify genes induced by S-28463. Out of 588 genes screened in this assay, only 13 genes were significantly induced by S-28463. Remarkably, virtually all of the induced genes are involved in macrophage activation and inflammatory response. This experimental approach defines the mechanism of action of this clinically relevant compound in the induction of microbicidal activity in macrophages and also potentially identifies novel genes associated with microbicidal activity in this cell type.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257027      PMCID: PMC90436          DOI: 10.1128/AAC.45.4.1137-1142.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action.

Authors:  S Buates; G Matlashewski
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

Review 2.  Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens.

Authors:  S J Green; C A Nacy; M S Meltzer
Journal:  J Leukoc Biol       Date:  1991-07       Impact factor: 4.962

3.  Identification and characterization of macrophage inflammatory protein 2.

Authors:  S D Wolpe; B Sherry; D Juers; G Davatelis; R W Yurt; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Macrophage inflammatory protein 1 modulates macrophage function.

Authors:  T J Fahey; K J Tracey; P Tekamp-Olson; L S Cousens; W G Jones; G T Shires; A Cerami; B Sherry
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

5.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

Review 6.  Macrophage inflammatory protein: its characteristics, biological properties and role in the regulation of haemopoiesis.

Authors:  B I Lord; C M Heyworth; L B Woolford
Journal:  Int J Hematol       Date:  1993-06       Impact factor: 2.490

7.  c-fos and tumor necrosis factor gene expression in Leishmania donovani-infected macrophages.

Authors:  A Descoteaux; G Matlashewski
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

8.  Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta.

Authors:  D D Taub; K Conlon; A R Lloyd; J J Oppenheim; D J Kelvin
Journal:  Science       Date:  1993-04-16       Impact factor: 47.728

9.  NF-kappa B subunit-specific regulation of the interleukin-8 promoter.

Authors:  C Kunsch; C A Rosen
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

10.  Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes.

Authors:  T J Schall; K Bacon; R D Camp; J W Kaspari; D V Goeddel
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  7 in total

1.  Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.

Authors:  Hector Nakayama; Philippe M Loiseau; Christian Bories; Susana Torres de Ortiz; Alicia Schinini; Elsa Serna; Antonieta Rojas de Arias; Mohamed A Fakhfakh; Xavier Franck; Bruno Figadère; Reynald Hocquemiller; Alain Fournet
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).

Authors:  J Moisan; W Wojciechowski; C Guilbault; C Lachance; S Di Marco; E Skamene; G Matlashewski; D Radzioch
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  [Topical immunomodulators in dermatology].

Authors:  N Meykadeh; U R Hengge
Journal:  Hautarzt       Date:  2003-07       Impact factor: 0.751

4.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

5.  Apoptotic Effect of Morphine, Imiquimod and Nalmefene on Promastigote, Infected and Uninfected Macrophages with Amastigote of Leishmania Major by Flow Cytometry.

Authors:  Parisa Ebrahimisadr; Fatemeh Ghaffarifar; John Horton; Abdolhosein Dalimi; Zohreh Sharifi
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

6.  First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

Authors:  Cesar Miranda-Verastegui; Gianfranco Tulliano; Theresa W Gyorkos; Wessmark Calderon; Elham Rahme; Brian Ward; Maria Cruz; Alejandro Llanos-Cuentas; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2009-07-28

7.  Effect of Imiquimod on Tachyzoites of Toxoplasma gondii and Infected Macrophages in vitro and in BALB/c Mice.

Authors:  Leila Zaki; Fatemeh Ghaffarifar; Zohreh Sharifi; John Horton; Javid Sadraei
Journal:  Front Cell Infect Microbiol       Date:  2020-07-31       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.